08:00 , Dec 11, 2000 |  BioCentury  |  Finance

Lump of coal in Euronext stocking

As stock exchanges increasingly move towards 24-7 trading, Euronext - the planned merger of the Paris, Brussels and Amsterdam exchanges - is moving in the opposite direction, proposing a twice-a-day auction system for listed stocks...
08:00 , Mar 22, 1999 |  BioCentury  |  Finance

Musical parents

- Oscar Wilde, The Importance Of Being Earnest Robertson Stephens will have a third parent company in as many years, as Fleet Financial Group announced plans to acquire Robbie's current parent, BancBoston, for $16 billion....
08:00 , Mar 1, 1999 |  BC Week In Review  |  Company News

Appligene Oncor SA, Quantum deal

Quantum acquired 80.2 percent of Appligene Oncor from Oncor Europe S.A.S. (Illkirch, France) for $1.25 million in cash. Appligene provides reagents for use in molecular biology research. Quantum will relocate its Quantum Biotechnology S.A. subsidiary...
08:00 , Mar 1, 1999 |  BC Week In Review  |  Company News

Quantum management update

(Appligene acquired, B3) Quantum Biotechnologies Inc., Montreal, Quebec   Business: Supply/Service   Hired: Mike Saunders as VP and general manager for European operations, formerly president of Appligene Oncor SA  ...
07:00 , Jun 29, 1998 |  BioCentury  |  Finance

Follow the money

Follow the money Companies trying to sell IPOs on U.S. markets are having a tough go at finding buyers. However, U.S. bioscience companies are having success selling equity to European investors. Stateside, Genzyme Molecular postponed...
07:00 , Oct 6, 1997 |  BioCentury  |  Finance

Euromarkets

Ebb & Flow Focus OXFORD - Just over five years ago, Europe's entrepreneurial bioscience companies had very little choice if they wanted to access public equity. It was either a case of cranking up the...
07:00 , Jul 21, 1997 |  BC Week In Review  |  Company News

Oncor, F. Hoffmann-La Roche deal

ONC's Appligene Oncor SA subsidiary (Strasbourg, France) signed a non-exclusive worldwide license agreement with Hoffmann-La Roche and its Roche Molecular Systems Inc. subsidiary (Somerville, N.J.) for polymerase chain reaction related research reagents. Appligene Oncor will...
08:00 , Dec 16, 1996 |  BC Week In Review  |  Clinical News

Oncor regulatory update

ONC received PMA approvals for its Inform HER-2/neu Gene Amplification Test in Spain, Portugal and Sweden. The test is used in the management of breast cancer. ONC will sell the test through its subsidiary, Appligene...
07:00 , Oct 3, 1994 |  BC Week In Review  |  Company News

Oncor deal

The genetic testing company acquired Appligene S.A., a French developer of molecular genetic products, for $2.2 million in cash, notes with an aggregate principal amount of $4.3 million and 636,000 shares of ONCR common stock....